Jun. 27 at 11:34 AM
$QDEL
If QuidelOrtho successfully sells Point-of-Care:
It becomes:
~
$2.1B revenue diagnostics company
~
$520M EBITDA
~2× leverage
stable hospital + lab exposure
Valuation of the “pure diagnostics company”
Pure hospital diagnostics companies typically trade at:
EV/EBITDA: 10×–14×
depending on growth + margin stability
Let’s apply ranges:
EBITDA: ~
$520M
Conservative (10×)EV =
$5.2B
Base (12×)EV =
$6.2B
Bull (14×)EV =
$7.3B
Per-share value (≈68M shares)Case
Share price
Bear~
$60
Base~
$75
Bull~
$90
